Aerovate Therapeutics Inc

NASDAQ AVTE

Download Data

Aerovate Therapeutics Inc Current Ratio 3 year CAGR for the quarter ending March 31, 2024: 7.27%

Aerovate Therapeutics Inc Current Ratio 3 year CAGR is 7.27% for the quarter ending March 31, 2024. The current ratio assesses a company's short-term liquidity and its ability to cover its current liabilities with its current assets. It is calculated by dividing current assets by current liabilities. This ratio indicates the number of times a company's current assets can cover its current liabilities. A higher current ratio suggests better liquidity and a stronger ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Aerovate Therapeutics Inc Current Ratio for the quarter ending March 31, 2023 was 11.33, a -67.86% change year over year.
  • Aerovate Therapeutics Inc Current Ratio for the quarter ending March 31, 2022 was 35.27, a 554.47% change year over year.
  • Aerovate Therapeutics Inc Current Ratio for the quarter ending March 31, 2021 was 5.39.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email